Scarica l'app Stockscreener
33.12
13.23%
3.87
Dopo l'orario di chiusura:
33.40
0.28
+0.85%
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Will Mineralys Therapeutics Inc. benefit from AI trendsJuly 2025 Weekly Recap & Daily Stock Trend Reports - khodrobank.com
Mineralys Therapeutics Announces Public Offering of Shares - TipRanks
Mineralys Therapeutics launches $175M public offering - MSN
Mineralys: Soaring As Rival's Hypertension Data Falls ShortBuy The Next Dip (MLYS) - Seeking Alpha
Stock Market Update: Bruker, Mineralys Therapeutics, and Other Big Stocks Moving Lower in Wednesday's Pre-Market Session - AInvest
Can volume confirm reversal in Mineralys Therapeutics Inc.Product Launch & Accurate Buy Signal Alerts - Newser
Mineralys In The Money As Lorundrostat Gets Close To Market - insights.citeline.com
Mineralys’ strategic stock sale; Gilead, Shoreline partnership ends - Endpoints News
Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak - Yahoo Finance
Mineralys Therapeutics prices upsized $250M stock offering - MSN
Short interest data insights for Mineralys Therapeutics Inc.July 2025 Gainers & Free Reliable Trade Execution Plans - Newser
Latham Advises Mineralys Therapeutics on Upsized US$250 Million Underwritten Public Offering of Common Stock - Latham & Watkins LLP
How to interpret RSI for Mineralys Therapeutics Inc. stockM&A Rumor & Risk Managed Investment Entry Signals - Newser
Institutional scanner results for Mineralys Therapeutics Inc.Portfolio Return Report & Long-Term Growth Plans - Newser
Can Mineralys Therapeutics Inc. disrupt its industryGold Moves & Growth Focused Entry Point Reports - khodrobank.com
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Identifying reversal signals in Mineralys Therapeutics Inc.2025 Key Lessons & Safe Entry Trade Signal Reports - Newser
Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 - Investing.com
Will Mineralys Therapeutics Inc. announce a stock splitPortfolio Gains Summary & Technical Pattern Recognition Alerts - khodrobank.com
Mineralys Therapeutics shares fall 6.38% premarket after suspending prospectus supplement for ATM equity offering. - AInvest
Is Mineralys Therapeutics Inc. still worth holding after the dip2025 Trade Ideas & Weekly Top Performers Watchlists - Newser
Q&A with Jon Congleton, CEO of Mineralys Therapeutics - The Pharma Letter
Order flow analysis tools used on Mineralys Therapeutics Inc.Weekly Market Outlook & Stepwise Trade Signal Implementation - Newser
What high frequency data says about Mineralys Therapeutics Inc.July 2025 PreEarnings & Long-Term Investment Growth Plans - Newser
Mineralys Therapeutics Prices $250 Million Notes Offering - MarketScreener
Mineralys Therapeutics stock hits all-time high at 22.0 USD By Investing.com - Investing.com Canada
What MACD and RSI say about Mineralys Therapeutics Inc.Earnings Overview Summary & Weekly Watchlist for Consistent Profits - Newser
How sentiment analysis helps forecast Mineralys Therapeutics Inc.July 2025 Reactions & Low Risk Entry Point Guides - Newser
Published on: 2025-09-03 02:21:26 - Newser
How moving averages guide Mineralys Therapeutics Inc. tradingEarnings Overview Report & Safe Entry Point Identification - Newser
Key metrics from Mineralys Therapeutics Inc.’s quarterly dataJuly 2025 Drop Watch & Stepwise Trade Execution Plans - Newser
Chart overlay techniques for tracking Mineralys Therapeutics Inc.Quarterly Market Summary & Daily Price Action Insights - Newser
Using RSI to spot recovery in Mineralys Therapeutics Inc.July 2025 Patterns & Technical Confirmation Trade Alerts - Newser
Mineralys Therapeutics' $250M Upsized Equity Raise: A Strategic Inflection Point for Hypertension Innovation - AInvest
Published on: 2025-09-03 00:47:22 - Newser
Published on: 2025-09-03 00:45:39 - Newser
Jefferies expects Mineralys stock to trade up following AstraZeneca data - MSN
$250 Million Stock Offering: Hypertension Drug Developer Mineralys Prices Upsized Public Share Sale - Stock Titan
Mineralys Therapeutics Prices Upsized Public Offering Of 9.80 Mln At $25.50/shr - Nasdaq
Mineralys Therapeutics Announces Upsized Public Offering of Common Stock Raising Approximately $250 Million - Quiver Quantitative
Mineralys Therapeutics announces pricing of upsized $250.0 million underwritten public offering of common stock - MarketScreener
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock - GlobeNewswire
Does Mineralys Therapeutics Inc. align with a passive investing strategyQuarterly Profit Summary & Advanced Swing Trade Entry Alerts - khodrobank.com
Mineralys Stock Surges 86.43% on $0.43B Trading Volume Ranked 256th in Market Activity as $175M Public Offering Drives Institutional Confidence - AInvest
Mineralys Therapeutics to Announce Q2 Financial Results on August 12 - MSN
AstraZeneca's Blood Pressure Drug Baxdrostat Shows Positive Trial Results, Boosting Mineralys Therapeutics Shares by 85% - AInvest
Mineralys Therapeutics announces proposed public offering of common stock - MarketScreener
Mineralys Therapeutics Halts Common Stock Offering - TipRanks
Mineralys Therapeutics down on $175 mln stock offering plans - TradingView
Is Mineralys Therapeutics Inc. reversing from oversold territory2025 Stock Rankings & Low Drawdown Momentum Ideas - Newser
Mineralys Therapeutics launches $175 million public stock offering - Investing.com
Mineralys Therapeutics Launches $175 Million Public Share Offering - MarketScreener
Mineralys Therapeutics announces $175M common stock offering - TipRanks
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire
$175 Million Stock Offering: Mineralys Therapeutics Seeks Funding for Hypertension Drug Development - Stock Titan
Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug - MSN
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):